GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures

Core Insights - GRI Bio, Inc. has received U.S. Patent No. 12,528,775, enhancing its intellectual property protection for its immunomodulator compounds targeting inflammatory, fibrotic, and autoimmune diseases [1][2][3] Intellectual Property - The newly issued patent includes claims for a distinct class of proprietary compounds characterized by linked molecular structures forming pyrrolidine, piperidine, or azepane ring systems, which are a significant advancement over previous patents [2] - This patent strengthens GRI Bio's intellectual property estate, providing independent protection for a valuable subset of its chemistry platform [3] Product Development - GRI Bio is focused on advancing its lead program, GRI-0621, which is an RARβγ agonist aimed at treating idiopathic pulmonary fibrosis, a disease with significant unmet medical needs [4][5] - The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for systemic lupus erythematosus, supported by a library of over 500 proprietary compounds [5]